A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma
Bladder Cancer · 02.04.2016 · 2 (2) · 241-250
DOI: 10.3233/blc-150044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 02.04.2016. Verfasst von Deborah W Knapp und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN, USA; Purdue University Center for Cancer Research, Purdue Universi…. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Chemotherapy is expected to remain an important part of invasive urothelial carcinoma (UC) treatment. Strategies to enhance chemotherapy efficacy are needed.
Objective
To determine the chemotherapy-enhancing effects of a nonselective cyclooxygenase (COX) inhibitor on vinblastine in a naturally-occurring canine model of invasive UC.
Methods
With IACUC approval, privately-owned dogs with naturally-occurring histologically-diagnosed invasive UC, expected survival ≥6 weeks, and informed owner consent were randomly allocated to receive vinblastine (2.5 mg/m 2 intravenously every 2 weeks) plus piroxicam (0.3 mg/kg daily per os) or vinblastine alone (same dose) with the option to receive piroxicam alone when vinblastine failed. Scheduled evaluations included physical exam, standard laboratory analyses, thoracic radiography, abdominal ultrasonography, and standardized measurement of urinary tract tumors.
Results
Dogs receiving vinblastine alone ( n = 27) and vinblastine-piroxicam ( n = 24) were similar in age, sex, breed, tumor stage, and grade. Remission occurred more frequently ( P < 0.02) with vinblastine-piroxicam (58.3%) than with vinblastine alone (22.2%). The median progression free interval was 143 days with vinblastine alone and 199 days with the combination. Interestingly, the overall median survival time was significantly longer ( P < 0.03) in dogs receiving vinblastine alone followed by piroxicam alone ( n = 20, 531 days) than in dogs receiving the combination (299 days). Treatment was well tolerated in both arms.
Conclusions
Piroxicam significantly enhanced the activity of vinblastine in dogs with UC where the cancer closely mimics the human condition, clearly justifying further study. The study suggest the potential importance of tracking COX inhibitor use in patients in clinical trials as COX inhibitors could affect treatment response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN, USA; Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN, USA.
- Department of Comparative Pathobiology, Purdue University , West Lafayette, IN, USA.
- Indiana Veterinary Imaging, Indianapolis, IN, USA.
- Department of Veterinary Clinical Sciences, Purdue University , West Lafayette, IN, USA.
Zitieren
APA
Knapp, D. W., Ruple-Czerniak, A., Ramos-Vara, J. A., Naughton, J. F., Fulkerson, C. M., & Honkisz, S. I. (2016). A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma. Bladder Cancer, 2(2), 241-250. https://doi.org/10.3233/blc-150044
Vancouver
Knapp DW, Ruple-Czerniak A, Ramos-Vara JA, Naughton JF, Fulkerson CM, Honkisz SI. A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma. Bladder Cancer. 2016;2(2):241-250. doi:10.3233/blc-150044
BibTeX
@article{Knapp2016,
author = {Knapp, Deborah W and Ruple-Czerniak, Audrey and Ramos-Vara, José A and Naughton, James F and Fulkerson, Christopher M and Honkisz, Sonia I},
title = {A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma},
journal = {Bladder Cancer},
year = {2016},
volume = {2},
number = {2},
pages = {241--250},
doi = {10.3233/blc-150044}
}
EUVIMED